Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto):
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Erlangen
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
2016
|
| Schlagworte: | |
| Online-Zugang: | Volltext Volltext Volltext |
| Beschreibung: | Aus: Annals of Oncology 25.12 (2014): S. 2363-2372. <http://annonc.oxfordjournals.org/content/25/12/2363.abstract> Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. This publication is with permission of the rights owner freely accessible due to an Alliance licence or a national licence (funded by the DFG, German Research Foundation) respectively. |
| Beschreibung: | 1 Online-Ressource |
| Format: | Langzeitarchivierung gewährleistet, LZA |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043794622 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 160926s2016 gw |||| o||u| ||||||eng d | ||
| 015 | |a 16,O10 |2 dnb | ||
| 016 | 7 | |a 1113290943 |2 DE-101 | |
| 024 | 7 | |a urn:nbn:de:bvb:29-opus4-74543 |2 urn | |
| 035 | |a (OCoLC)959657654 | ||
| 035 | |a (DE-599)DNB1113290943 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BY | ||
| 049 | |a DE-29 | ||
| 082 | 0 | |a 610 |2 23 | |
| 084 | |a 610 |2 sdnb | ||
| 100 | 1 | |a Minckwitz, G. von |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto) |c G. von Minckwitz ; S. Loibl ; M. Untch ; H. Eidtmann ; M. Rezai ; Peter A. Fasching ; H. Tesch ; H. Eggemann ; I. Schrader ; K. Kittel ; C. Hanusch ; J. Huober ; C. Solbach ; C. Jackisch ; G. Kunz ; J. U. Blohmer ; M. Hauschild ; T. Fehm ; V. Nekljudova ; B. Gerber |
| 264 | 1 | |a Erlangen |b Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) |c 2016 | |
| 300 | |a 1 Online-Ressource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Aus: Annals of Oncology 25.12 (2014): S. 2363-2372. <http://annonc.oxfordjournals.org/content/25/12/2363.abstract> | ||
| 500 | |a Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. | ||
| 500 | |a This publication is with permission of the rights owner freely accessible due to an Alliance licence or a national licence (funded by the DFG, German Research Foundation) respectively. | ||
| 538 | |a Langzeitarchivierung gewährleistet, LZA | ||
| 653 | |a bevacizumab | ||
| 653 | |a everolimus | ||
| 653 | |a neoadjuvant chemotherapy | ||
| 653 | |a disease-free survival | ||
| 653 | |a overall survival | ||
| 700 | 1 | |a Loibl, S. |e Verfasser |4 aut | |
| 700 | 1 | |a Untch, M. |e Verfasser |4 aut | |
| 700 | 1 | |a Eidtmann, H. |e Verfasser |4 aut | |
| 700 | 1 | |a Rezai, M. |e Verfasser |4 aut | |
| 700 | 1 | |a Fasching, Peter A. |e Verfasser |4 aut | |
| 700 | 1 | |a Tesch, H. |e Verfasser |4 aut | |
| 700 | 1 | |a Eggemann, H. |e Verfasser |4 aut | |
| 700 | 1 | |a Schrader, I. |e Verfasser |4 aut | |
| 700 | 1 | |a Kittel, K. |e Verfasser |4 aut | |
| 700 | 1 | |a Hanusch, C. |e Verfasser |4 aut | |
| 700 | 1 | |a Huober, J. |e Verfasser |4 aut | |
| 700 | 1 | |a Solbach, C. |e Verfasser |4 aut | |
| 700 | 1 | |a Jackisch, C. |e Verfasser |4 aut | |
| 700 | 1 | |a Kunz, G. |e Verfasser |4 aut | |
| 700 | 1 | |a Blohmer, J. U. |e Verfasser |4 aut | |
| 700 | 1 | |a Hauschild, M. |e Verfasser |4 aut | |
| 700 | 1 | |a Fehm, T. |e Verfasser |4 aut | |
| 700 | 1 | |a Nekljudova, V. |e Verfasser |4 aut | |
| 700 | 1 | |a Gerber, B. |e Verfasser |4 aut | |
| 856 | 4 | 0 | |u https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-74543 |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://d-nb.info/1113290943/34 |x Langzeitarchivierung Nationalbibliothek |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://open.fau.de/handle/openfau/7454 |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ebook | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029205536 | ||
Datensatz im Suchindex
| _version_ | 1804176636507062272 |
|---|---|
| any_adam_object | |
| author | Minckwitz, G. von Loibl, S. Untch, M. Eidtmann, H. Rezai, M. Fasching, Peter A. Tesch, H. Eggemann, H. Schrader, I. Kittel, K. Hanusch, C. Huober, J. Solbach, C. Jackisch, C. Kunz, G. Blohmer, J. U. Hauschild, M. Fehm, T. Nekljudova, V. Gerber, B. |
| author_facet | Minckwitz, G. von Loibl, S. Untch, M. Eidtmann, H. Rezai, M. Fasching, Peter A. Tesch, H. Eggemann, H. Schrader, I. Kittel, K. Hanusch, C. Huober, J. Solbach, C. Jackisch, C. Kunz, G. Blohmer, J. U. Hauschild, M. Fehm, T. Nekljudova, V. Gerber, B. |
| author_role | aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
| author_sort | Minckwitz, G. von |
| author_variant | g v m gv gvm s l sl m u mu h e he m r mr p a f pa paf h t ht h e he i s is k k kk c h ch j h jh c s cs c j cj g k gk j u b ju jub m h mh t f tf v n vn b g bg |
| building | Verbundindex |
| bvnumber | BV043794622 |
| collection | ebook |
| ctrlnum | (OCoLC)959657654 (DE-599)DNB1113290943 |
| dewey-full | 610 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 610 - Medicine and health |
| dewey-raw | 610 |
| dewey-search | 610 |
| dewey-sort | 3610 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03138nmm a2200697zc 4500</leader><controlfield tag="001">BV043794622</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">160926s2016 gw |||| o||u| ||||||eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">16,O10</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1113290943</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">urn:nbn:de:bvb:29-opus4-74543</subfield><subfield code="2">urn</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)959657654</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1113290943</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BY</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Minckwitz, G. von</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)</subfield><subfield code="c">G. von Minckwitz ; S. Loibl ; M. Untch ; H. Eidtmann ; M. Rezai ; Peter A. Fasching ; H. Tesch ; H. Eggemann ; I. Schrader ; K. Kittel ; C. Hanusch ; J. Huober ; C. Solbach ; C. Jackisch ; G. Kunz ; J. U. Blohmer ; M. Hauschild ; T. Fehm ; V. Nekljudova ; B. Gerber</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Erlangen</subfield><subfield code="b">Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)</subfield><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Aus: Annals of Oncology 25.12 (2014): S. 2363-2372. <http://annonc.oxfordjournals.org/content/25/12/2363.abstract></subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">This publication is with permission of the rights owner freely accessible due to an Alliance licence or a national licence (funded by the DFG, German Research Foundation) respectively.</subfield></datafield><datafield tag="538" ind1=" " ind2=" "><subfield code="a">Langzeitarchivierung gewährleistet, LZA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bevacizumab</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">everolimus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neoadjuvant chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">disease-free survival</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">overall survival</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Loibl, S.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Untch, M.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eidtmann, H.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rezai, M.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fasching, Peter A.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tesch, H.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eggemann, H.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schrader, I.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kittel, K.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hanusch, C.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huober, J.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Solbach, C.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jackisch, C.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kunz, G.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Blohmer, J. U.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hauschild, M.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fehm, T.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nekljudova, V.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gerber, B.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-74543</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://d-nb.info/1113290943/34</subfield><subfield code="x">Langzeitarchivierung Nationalbibliothek</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://open.fau.de/handle/openfau/7454</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ebook</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029205536</subfield></datafield></record></collection> |
| id | DE-604.BV043794622 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:35:20Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029205536 |
| oclc_num | 959657654 |
| open_access_boolean | 1 |
| owner | DE-29 |
| owner_facet | DE-29 |
| physical | 1 Online-Ressource |
| psigel | ebook |
| publishDate | 2016 |
| publishDateSearch | 2016 |
| publishDateSort | 2016 |
| publisher | Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) |
| record_format | marc |
| spelling | Minckwitz, G. von Verfasser aut Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto) G. von Minckwitz ; S. Loibl ; M. Untch ; H. Eidtmann ; M. Rezai ; Peter A. Fasching ; H. Tesch ; H. Eggemann ; I. Schrader ; K. Kittel ; C. Hanusch ; J. Huober ; C. Solbach ; C. Jackisch ; G. Kunz ; J. U. Blohmer ; M. Hauschild ; T. Fehm ; V. Nekljudova ; B. Gerber Erlangen Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) 2016 1 Online-Ressource txt rdacontent c rdamedia cr rdacarrier Aus: Annals of Oncology 25.12 (2014): S. 2363-2372. <http://annonc.oxfordjournals.org/content/25/12/2363.abstract> Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. This publication is with permission of the rights owner freely accessible due to an Alliance licence or a national licence (funded by the DFG, German Research Foundation) respectively. Langzeitarchivierung gewährleistet, LZA bevacizumab everolimus neoadjuvant chemotherapy disease-free survival overall survival Loibl, S. Verfasser aut Untch, M. Verfasser aut Eidtmann, H. Verfasser aut Rezai, M. Verfasser aut Fasching, Peter A. Verfasser aut Tesch, H. Verfasser aut Eggemann, H. Verfasser aut Schrader, I. Verfasser aut Kittel, K. Verfasser aut Hanusch, C. Verfasser aut Huober, J. Verfasser aut Solbach, C. Verfasser aut Jackisch, C. Verfasser aut Kunz, G. Verfasser aut Blohmer, J. U. Verfasser aut Hauschild, M. Verfasser aut Fehm, T. Verfasser aut Nekljudova, V. Verfasser aut Gerber, B. Verfasser aut https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-74543 Resolving-System kostenfrei Volltext http://d-nb.info/1113290943/34 Langzeitarchivierung Nationalbibliothek kostenfrei Volltext https://open.fau.de/handle/openfau/7454 Verlag kostenfrei Volltext |
| spellingShingle | Minckwitz, G. von Loibl, S. Untch, M. Eidtmann, H. Rezai, M. Fasching, Peter A. Tesch, H. Eggemann, H. Schrader, I. Kittel, K. Hanusch, C. Huober, J. Solbach, C. Jackisch, C. Kunz, G. Blohmer, J. U. Hauschild, M. Fehm, T. Nekljudova, V. Gerber, B. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto) |
| title | Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto) |
| title_auth | Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto) |
| title_exact_search | Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto) |
| title_full | Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto) G. von Minckwitz ; S. Loibl ; M. Untch ; H. Eidtmann ; M. Rezai ; Peter A. Fasching ; H. Tesch ; H. Eggemann ; I. Schrader ; K. Kittel ; C. Hanusch ; J. Huober ; C. Solbach ; C. Jackisch ; G. Kunz ; J. U. Blohmer ; M. Hauschild ; T. Fehm ; V. Nekljudova ; B. Gerber |
| title_fullStr | Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto) G. von Minckwitz ; S. Loibl ; M. Untch ; H. Eidtmann ; M. Rezai ; Peter A. Fasching ; H. Tesch ; H. Eggemann ; I. Schrader ; K. Kittel ; C. Hanusch ; J. Huober ; C. Solbach ; C. Jackisch ; G. Kunz ; J. U. Blohmer ; M. Hauschild ; T. Fehm ; V. Nekljudova ; B. Gerber |
| title_full_unstemmed | Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto) G. von Minckwitz ; S. Loibl ; M. Untch ; H. Eidtmann ; M. Rezai ; Peter A. Fasching ; H. Tesch ; H. Eggemann ; I. Schrader ; K. Kittel ; C. Hanusch ; J. Huober ; C. Solbach ; C. Jackisch ; G. Kunz ; J. U. Blohmer ; M. Hauschild ; T. Fehm ; V. Nekljudova ; B. Gerber |
| title_short | Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto) |
| title_sort | survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for her2 negative primary breast cancer gbg 44 geparquinto |
| url | https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-74543 http://d-nb.info/1113290943/34 https://open.fau.de/handle/openfau/7454 |
| work_keys_str_mv | AT minckwitzgvon survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT loibls survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT untchm survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT eidtmannh survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT rezaim survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT faschingpetera survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT teschh survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT eggemannh survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT schraderi survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT kittelk survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT hanuschc survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT huoberj survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT solbachc survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT jackischc survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT kunzg survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT blohmerju survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT hauschildm survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT fehmt survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT nekljudovav survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto AT gerberb survivalafterneoadjuvantchemotherapywithorwithoutbevacizumaboreverolimusforher2negativeprimarybreastcancergbg44geparquinto |